Related Experiment Video
Updated: Apr 11, 2026

An In Vitro Caseum Binding Assay that Predicts Drug Penetration in Tuberculosis Lesions
Published on: May 8, 2017
Trabectedin clinical cases: use according to indication in diverse clinical scenarios
Giovanni Grignani1, Javier Martín-Broto2, Markus Schuler3
11Medical Oncology Unit, Candiolo Cancer Institute - FPO, IRCCS, Italy.
Background:
Key distinguishing characteristics of trabectedin in the treatment of advanced soft tissue sarcoma are its prolonged tumor control activity in multiple histological subtypes, positive outcomes in translocation-related sarcomas, maintenance of response, option to rechallenge after treatment interruption and lack of cumulative toxicity. Trabectedin is indicated for use in advanced soft tissue sarcoma after failure of anthracyclines and ifosfamide, or as front-line treatment in patients unsuited to receive these agents.
Methods:
In this review, cases studies are presented in which trabectedin was used according to its indication but in diverse clinical settings.
Results:
As second-line treatment of uterine leiomyosarcoma, trabectedin produced prolonged tumor control with good quality of life. In treatment of recurrent synovial sarcoma, the best objective response (partial response) and longest disease control (37 months) was achieved under treatment with trabectedin. As neoadjuvant treatment of undifferentiated pleomorphic sarcoma in a patient unsuited to receive doxorubicin-based chemotherapy, trabectedin induced a pathological response with 85% of necrosis.
Conclusion:
These cases illustrate the broad range of indications for trabectedin in advanced soft tissue sarcoma and highlight how its unique characteristics can be optimized to achieve maximum clinical benefit.
Insights
Trabectedin offers prolonged tumor control and maintains quality of life in advanced soft tissue sarcoma patients. This drug demonstrates efficacy across various subtypes, including uterine leiomyosarcoma and synovial sarcoma.
Area of Science:
- Oncology
- Pharmacology
Background:
- Trabectedin is indicated for advanced soft tissue sarcoma (STS) post-anthracycline/ifosfamide failure or as first-line for ineligible patients.
- Key features include prolonged tumor control, efficacy in translocation-related sarcomas, response maintenance, rechallenge option, and minimal cumulative toxicity.
Observation:
- Case studies reviewed trabectedin use in diverse clinical settings within its approved indications.
- Specific cases involved second-line treatment for uterine leiomyosarcoma, recurrent synovial sarcoma, and neoadjuvant therapy for undifferentiated pleomorphic sarcoma.
Findings:
- Trabectedin provided prolonged tumor control and good quality of life in uterine leiomyosarcoma.
- Recurrent synovial sarcoma achieved best objective response and longest disease control (37 months) with trabectedin.
- Neoadjuvant trabectedin in undifferentiated pleomorphic sarcoma resulted in 85% tumor necrosis.
Implications:
- These cases highlight trabectedin's broad utility in advanced STS.
- Optimizing trabectedin's unique characteristics can maximize clinical benefit in soft tissue sarcoma treatment.
More Related Videos
06:49Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians
Published on: March 14, 2014
06:15Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Drugs that Stabilize Microtubules
Drugs that Destabilize Microtubules
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Anthelminthic Agents